How to Build CHD@ZJU

CHD related Articles were retrieved from Pubmed, by entering keywords "coronary heart disease" and constrict the publish date from 2000/1/1 to now (2013/1/23). As a result, totally 115898 articles were found and their abstracts were downloaded for text mining. Since some articles didn't contain abstracts, only 88396 abstracts remained.

The text-mining process to get CHD related genes could be divided in to 5 following steps:

  • 1) Extracting all keywords from abstracts and ignoring those keywords start with numbers. 101402 keywords were extracted.

  • 2) Input these keywords into Gene library in ArrayTrack and find possible related genes. 4674 genes were then found.

  • 3) Put these 4674 genes again into pubmed abstracts to find related aticles. Only genes which offical name or there keyword description (such as prolactin for gene PRL) could be found in the abstract would be remained. As a result, 1247 genes were remained.

  • 4) Manually examined on the 1247 genes to validate it was acutally related to CHD. Some genes would be filtered if it represents other meanings (such as gene CAD, Entrez ID:790, carbamoyl-phosphate synthetase 2, is mostly meant coronary arterial disease in articles). 681 genes were then validated with at least one reference.

  • 5) All genes was compared with 1078 CHD genes in RGD database, and 370 genes were overlapped. These 370 genes were labels as "RGD_Supported" and the other 293 genes were labels as "REFERED". All 663 genes had supported references in CHD@ZJU which were examined by step 4.
  • How To contact Us

    Collaboration Information: Prof. Xiaohui Fan (fanxh@zju.edu.cn)

    Website using assistance : Leihong Wu (11019004@zju.edu.cn)



    Basic Information

    Gene Name: ESR1

    Description: estrogen receptor 1

    Entrez Gene ID: 2099

    SwissProt Acc Number: P03372

    RefSeq: NM_000125

    It was suspected to be CHD related:

    ..a statistically significant relationship between the ESR1 c.454-397T>C polymorphism and CAD were found independent of known CAD risk factors in a Turkish population...

    From PMID: 18294052, in Journal Genet Test , 2007


    References

    There were 22 potential papers with ESR1 and CHD.

    PMIDTitleJournalsDetails
    24171864 "Integrating multiple oestrogen receptor alpha ChIP studies: overlap with disease susceptibility regions, DNase I hypersensitivity peaks and gene expression."BMC medical genomicsMore Details
    23471591 Meta-analysis of the association of the rs2234693 and rs9340799 polymorphisms of estrogen receptor alpha gene with coronary heart disease risk in Chinese Han population.International journal of medical sciencesMore Details
    21984528 Post-genomic update on a classical candidate gene for coronary artery disease: ESR1.Circulation. Cardiovascular geneticsMore Details
    21658281 GWAS for discovery and replication of genetic loci associated with sudden cardiac arrest in patients with coronary artery disease.BMC cardiovascular disordersMore Details
    20153472 "ESR1 genetic variants, haplotypes and the risk of coronary heart disease and ischemic stroke in the Finnish population: a prospective follow-up study."AtherosclerosisMore Details
    19446283 Lipid profile and inflammatory markers associated with estrogen receptor alpha PvuII and XbaI gene polymorphisms.Translational research : the journal of laboratory and clinical medicineMore Details
    19318036 Association of estrogen receptor alpha gene polymorphism with the presence of coronary artery disease documented by coronary angiography.Clinical biochemistryMore Details
    19608186 Qualitative assessment of previous evidence and an updated meta-analysis confirms lack of association between the ESR1 rs2234693 (PvuII) variant and coronary heart disease in men and women.AtherosclerosisMore Details
    18360040 Haplotype-based case-control study of estrogen receptor alpha (ESR1) gene and pregnancy-induced hypertension.Hypertension research : official journal of the Japanese Society of HypertensionMore Details
    18294052 The relationship of the ESR1 gene polymorphisms with the presence of coronary artery disease determined by coronary angiography.Genetic testingMore Details
    17903303 Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study.BMC medical geneticsMore Details
    17558892 Estrogen receptor-1 genotype is related to coronary intima thickness in young to middle-aged women.Scandinavian journal of clinical and laboratory investigationMore Details
    16551651 The association of oestrogen receptor alpha-haplotypes with cardiovascular risk factors in the British Women's Heart and Health Study.European heart journalMore Details
    16612467 Estrogen receptor 1 gene polymorphisms and coronary artery disease in the Brazilian population.Brazilian journal of medical and biological research = Revista brasileira deMore Details
    16099331 Genetic polymorphisms of estrogen receptors in patients with premature coronary artery disease.Archives of medical researchMore Details
    16203927 No replication of association between estrogen receptor alpha gene polymorphisms and susceptibility to myocardial infarction in a large sample of patients of European descent.CirculationMore Details
    16179580 Estrogen receptor alpha gene variation and the risk of stroke.Stroke; a journal of cerebral circulationMore Details
    15811432 Gene variants for osteoporosis and their pleiotropic effects in aging.Molecular aspects of medicineMore Details
    16159931 Estrogen receptor alpha gene polymorphisms are associated with the angiographic extent of coronary artery disease.The Journal of clinical endocrinology and metabolismMore Details
    15517129 Estrogen receptor genotype modulates myocardial perfusion in young men."Journal of molecular medicine (Berlin, Germany)"More Details
    14600184 Association between estrogen receptor alpha gene variation and cardiovascular disease.JAMA : the journal of the American Medical AssociationMore Details
    11894143 Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study."Journal of molecular medicine (Berlin, Germany)"More Details

    NOTEs: These result is mostly from TEXT-MINING and there might have mismatches.



    PPI interactions

    There were totally 343 unique genes interacted with ESR1. Show PPI network

    Gene nameInteraction typereference PMIDCHD relation
    DNTTIP2 Two-hybrid15047147 No
    XBP1 Reconstituted Complex12954762 No
    PHB2 Two-hybrid12943695|15140878|10938099,15140878 No
    TDG Reconstituted Complex12874288 No
    MED24 Affinity Capture-MS12837248|11867769|11867769 No
    TRRAP Affinity Capture-MS12837248|16260778|16260778|12738788|12738788 No
    NCOA2 Affinity Capture-Western12837248|11937504|11250900|11250900|12612084|18499756|16645043|12714702|15657427|9192892|12630920|12554772|11376110|11014206|11014206|9774463 No
    MED1 Affinity Capture-Western12837248|11867769|11867769|15886699|10770935|10770935|10760302|10760302|12738788|12738788 No
    SAFB2 Reconstituted Complex12660241 No
    MNAT1 Reconstituted Complex12527756 No
    FKBP5 Reconstituted Complex9222609 No
    FKBP4 Reconstituted Complex9222609 No
    HSP90AA1 Reconstituted Complex9222609|11911945|16037132|15538384|20353944|21503962|18388150 CHD related
    HSPA4 Reconstituted Complex9222609|15538384|21503962|15556606|15556606|15556606 No
    PPID Reconstituted Complex9222609 No
    PTGES3 Reconstituted Complex9222609|18388150 No
    Nsd1 Reconstituted Complex9628876|9628876 No
    CDC25B Two-hybrid11689696|11689696|11689696 No
    MGMT Affinity Capture-Western11564893|11564893 No
    TRIP4 Reconstituted Complex10454579 No
    NCOA1 Reconstituted Complex11003650|11113179|9427757|11867769|11250900|11250900|12714702|12714702|10760302|9773983|9773983|9259327|9192902|9192892|9192892|12738788|12738788|12630920|12554772|11376110|11014206|11014206|20608937|9774463 No
    CREBBP Reconstituted Complex11113179|11782371|11782371|18765668|17400812 No
    PRDM2 Affinity Capture-Western10706618|15282304|19746436 No
    KDM5A Reconstituted Complex11358960|11358960 No
    ESR1 Two-hybrid12198596|19117995|20353944|12554772|10567404,11953755,10409727 CHD related
    NR2C2 Reconstituted Complex11844790 No
    MAPK1 Reconstituted Complex12093745 CHD related
    MDM2 Reconstituted Complex10766163|12897156|17545634|17545634|11178989 CHD related
    NRIP1 Reconstituted Complex7641693|8887632|16439465 No
    STAT3 Affinity Capture-Western11429412 CHD related
    NGG1 Two-hybrid12034840|12034840 No
    CAV1 Reconstituted Complex11563984|11563984 CHD related
    FOXO1 Two-hybrid11435445|11435445|11353774|22266855 CHD related
    FOXO4 Reconstituted Complex11435445 No
    PIK3R1 Affinity Capture-Western11689445 CHD related
    BAG1 Reconstituted Complex8524784|15538384|18388150 No
    PRMT2 Reconstituted Complex12039952|12039952 No
    SMAD2 Affinity Capture-Western11555647|20207742 CHD related
    MED12 Affinity Capture-Western11867769|11867769 No
    MED14 Affinity Capture-Western11867769|11867769|10770935 No
    MED23 Affinity Capture-Western11867769|11867769 No
    MED16 Affinity Capture-Western11867769|11867769 No
    MED6 Affinity Capture-Western11867769|11867769 No
    MED20 Affinity Capture-Western11867769|11867769 No
    MED10 Affinity Capture-Western11867769|11867769 No
    MED17 Reconstituted Complex11867769 No
    MED7 Reconstituted Complex11867769 No
    MED21 Reconstituted Complex11867769 No
    MED13 Reconstituted Complex11867769 No
    CCNC Affinity Capture-Western11867769|11867769 No
    CDK8 Reconstituted Complex11867769 No
    DDX17 Reconstituted Complex11250900|11250900|11250900|11250900|12738788 No
    TRAM1 Two-hybrid12612084|11014206|11014206 No
    UBC Affinity Capture-Western17418098|16314411|15538384|21503962|19383985|19383985|19887647|21572428|22865929|17311814|18388150|17545634|12554766|19122208|18414007|23041672 No
    MUC1 Affinity Capture-Western16427018 No
    UBE3A Affinity Capture-Western16314411 No
    STUB1 Affinity Capture-Western16037132|15538384|15538384|18388150|16037132 No
    HSPA8 Affinity Capture-Western16037132|15538384|20308691 CHD related
    HDAC4 Reconstituted Complex19893013|16051668|16051668 CHD related
    HDAC5 Reconstituted Complex19893013 No
    HDAC9 Reconstituted Complex19893013 No
    SUMO1 Affinity Capture-Western15961505|15961505 No
    FLII Reconstituted Complex19720835 No
    KLF5 Affinity Capture-Western19569049 CHD related
    SMYD3 Reconstituted Complex19509295|19509295 No
    MYOD1 Affinity Capture-Western18765668 No
    TOP2B Affinity Capture-Western16794079 No
    PRKDC Affinity Capture-Western16794079 No
    PARP1 Affinity Capture-Western16794079 CHD related
    XRCC5 Affinity Capture-Western16794079 No
    XRCC6 Affinity Capture-Western16794079 No
    MEN1 Two-hybrid16651450|16651450 No
    SP3 Affinity Capture-Western16651265|10816575 No
    RELA Affinity Capture-Western16497877|17932106|17932106|16331275|7651415 CHD related
    MYC Affinity Capture-Western16455494 CHD related
    RBBP7 Reconstituted Complex18577416 No
    RBBP4 Reconstituted Complex18577416 No
    MSH6 Affinity Capture-MS16260778 No
    MSH2 Affinity Capture-MS16260778|15886699|15886699 No
    KAT2A Affinity Capture-MS16260778|16260778 No
    LCOR Two-hybrid12535528|12535528|12535528|12535528 No
    TAF1A Reconstituted Complex12511607 No
    TAF1B Reconstituted Complex12511607|12511607 No
    SP2 Affinity Capture-Western15987735 No
    CDKN1A Reconstituted Complex15743834|17911387|12897156|17911387 CHD related
    IRS1 Affinity Capture-Western12821935 CHD related
    IRS2 Affinity Capture-Western12821935 CHD related
    CITED1 Reconstituted Complex11581164|11581164 No
    GRIP1 Reconstituted Complex9773983|9773983 No
    GTF2B Reconstituted Complex9259327|7641693,9841876 No
    NCOR2 Reconstituted Complex9171229|20392877|12738788|12738788 No
    KDM1A Affinity Capture-Western17289570 No
    GSN Affinity Capture-MS20308691|20308691 No
    ACTB Affinity Capture-MS20308691|20308691 No
    NPM1 Affinity Capture-MS20308691|20308691 No
    ACTC1 Affinity Capture-MS20308691 CHD related
    RPL18 Affinity Capture-MS20308691 No
    RPLP0 Affinity Capture-MS20308691 No
    RPL7A Affinity Capture-MS20308691 No
    MYL6 Affinity Capture-MS20308691 No
    RPL7 Affinity Capture-MS20308691 No
    RPS4X Affinity Capture-MS20308691 No
    MYO1C Affinity Capture-MS20308691|20308691 No
    DDX3X Affinity Capture-MS20308691 No
    RPS9 Affinity Capture-MS20308691 No
    RPS8 Affinity Capture-MS20308691 No
    ACTR3 Affinity Capture-MS20308691|20308691 No
    ACTR2 Affinity Capture-MS20308691|20308691 No
    POLR2A Affinity Capture-Western20308691 No
    MBD2 Co-localization20300195 No
    RBBP6 Affinity Capture-Western20184719 No
    SGK3 Affinity Capture-RNA21084382 No
    BARD1 Affinity Capture-Western20060929 No
    OTUB1 Affinity Capture-Western19383985 No
    SMARCC2 Affinity Capture-Western18451880 No
    SMARCB1 Affinity Capture-Western18451880 No
    CHD3 Affinity Capture-Western18451880 No
    MTA3 Affinity Capture-Western18451880|18451880 No
    DUT Two-hybrid15604093|15604093 No
    NPPA Two-hybrid15604093|15604093 CHD related
    MTCH2 Two-hybrid15604093|15604093 No
    PNRC2 Two-hybrid15604093 No
    KIF1A Two-hybrid15604093|15604093 No
    MLL2 Affinity Capture-Western16603732|16603732|21502505|16603732 No
    RBBP5 Affinity Capture-Western16603732|16603732|21502505 No
    ASH2L Affinity Capture-Western16603732|16603732|21502505 No
    WDR5 Affinity Capture-Western16603732|16603732|21502505 No
    TUBB1 Affinity Capture-MS15556606|15556606 No
    TUBA1A Affinity Capture-Western15556606 No
    PSMC5 Reconstituted Complex8598193|8598193,14702340 No
    MPG Affinity Capture-MS14761960|14761960|14761960|14761960 No
    BCAR1 Affinity Capture-Western15020686|19331827|15020686 No
    PIK3R2 Affinity Capture-Western15020686 No
    ERBB2 Affinity Capture-Western15173068|15173068 CHD related
    SOS2 Affinity Capture-Western15173068 No
    FHL2 Two-hybrid15666801|15666801 No
    UBE2I Two-hybrid15666801|15666801 No
    PIAS1 Two-hybrid15666801 No
    ARHGDIA Affinity Capture-Western21447808 No
    PRKCZ Affinity Capture-Western18313384 No
    TFF1 Phenotypic Enhancement18313384 No
    BLOC1S1 Reconstituted Complex12639951 No
    EHMT2 Reconstituted Complex21984853 No
    TAF2 Two-hybrid9765300 No
    UIMC1 Two-hybrid17311814|17311814 No
    CBLL1 Two-hybrid20608937|20608937 No
    CUL3 Affinity Capture-Western18414007 No
    ANIB1 Affinity Capture-Western9774463 No
    ARID5A Two-hybrid15941852|15941852|15941852 No
    TRAF6 Affinity Capture-Western19331827 No
    TBL1XR1 Affinity Capture-Western16469706 No
    SIN3B Affinity Capture-Western16469706 No
    ANP32A Affinity Capture-Western15308690 No
    BCL3 Affinity Capture-Western16331275 No
    RAC3 Affinity Capture-Western16331275 No
    BDNF in vitro11923430 CHD related
    YWHAH in vitro11266503 No
    CALM2 in vivo11981030 No
    CALM3 in vivo11981030 No
    JUNB in vitro11477071 No
    TRIM28 in vitro9774463 No
    GNAI1 in vitro;in vivo11369763 CHD related
    NFKB1 in vitro7651415 CHD related
    JUND in vitro11477071 No
    SOS1 in vitro15173068 No
    SREBF1 in vitro;in vivo12021179 No
    TSC2 in vitro;in vivo15851513 No
    USF1 in vitro15111769 CHD related
    HNF4A in vitro;yeast 2-hybrid9717844 No
    SMAD4 in vivo;yeast 2-hybrid11555647,12576474 No
    PRKACA in vitro9891036 CHD related
    MAPK3 in vitro;in vivo12118371 CHD related
    FOXO3 in vitro;yeast 2-hybrid11435445 CHD related
    PIK3R3 in vivo15001646 No
    RARA in vitro;yeast 2-hybrid9717844,17641689 No
    SLC30A9 in vitro;in vivo15988012 No
    ESRRA in vitro9058380 No
    THRB in vitro9717844 No
    NR0B1 in vitro11053406 No
    TRIM59 in vitro;in vivo;yeast 2-hybrid15941852 No
    PIAS3 in vitro;in vivo11117529 No
    ZBTB17 in vitro11117529 No
    THRA in vitro;yeast 2-hybrid9717844 CHD related
    HEXIM1 in vivo15940264 No
    CCNT1 in vitro;in vivo15940264 No
    TUBB in vivo15556606 No
    TUBA1B in vivo15556606 No
    ARHGEF15 yeast 2-hybrid15604093 No
    POLR2D yeast 2-hybrid15604093 No
    EGFR in vitro11887937 CHD related
    PPARGC1B Two-hybrid11854298|11854298 No
    SMARCA4 Two-hybrid9099865|9099865 No
    DDX54 Two-hybrid12466272|12466272|12466272 No
    NCOA6 Reconstituted Complex10567404|10567404|11773444|10866662|10866662|10866662 No
    BRCA1 Co-localization11493692|11244506|11244506|12400015|11782371|16260778|16061635|20060929|19887647|15674350|17505062 CHD related
    NCOA4 Reconstituted Complex9892017 No
    RBM39 Reconstituted Complex11704680|11704680|15694343|11704680 No
    DDX5 Affinity Capture-Western10409727|10409727|19995069|12738788 No
    SRC Affinity Capture-Western11032808|11564893|15784253|15140878|14766010|14766010|17363140|7539106,12736255,15140878 CHD related
    COBRA1 Reconstituted Complex15342491|15342491|15342491 No
    GADD45G Reconstituted Complex10872826|10872826 No
    GADD45A Affinity Capture-Western10872826 No
    Gadd45b Reconstituted Complex10872826 No
    CTNNB1 Affinity Capture-Western15304487 CHD related
    PTEN Reconstituted Complex15205473 CHD related
    SAFB Reconstituted Complex15066997|10707955|10707955|21527249|10707955 No
    ZBTB16 Reconstituted Complex14521715|14521715 No
    PTMA Reconstituted Complex12943695 No
    SMARCD1 Reconstituted Complex12917342 No
    BAZ1B Affinity Capture-Western12837248 No
    AHR Affinity Capture-Western12612060|10620335|12612060,10620335,17392787 No
    EP300 Reconstituted Complex12479814|11782371|19838210|16645043|12574227|20388208|19887647|14761960|22227247|15308690|11782371 CHD related
    MTA1 Affinity Capture-Western12167865|12167865|16807247|12167865 No
    CCNH Affinity Capture-Western12527756 No
    SMARCE1 Affinity Capture-Western12145209|12145209|16538531|12145209 No
    SMARCA2 Two-hybrid9099865|9099865 No
    YWHAQ Reconstituted Complex11266503 No
    PELP1 Affinity Capture-Western11481323|14963108|11481323 No
    PRMT1 Reconstituted Complex11050077 No
    Nr1i2 Reconstituted Complex9489701 No
    POU2F1 Reconstituted Complex10480874|10480874 No
    POU2F2 Reconstituted Complex10480874 No
    STAT5A Reconstituted Complex11682624|15304355 No
    RBFOX2 Reconstituted Complex11875103 No
    DAP3 Reconstituted Complex10903152 No
    NR2F1 Affinity Capture-Western12093745|12093745 No
    TP53 Reconstituted Complex10766163|10766163 CHD related
    CDK7 Biochemical Activity10949034|15461668 No
    GTF2H1 Biochemical Activity10949034|10949034|10949034 No
    MVP Affinity Capture-Western9628887|9628887 No
    ESR2 Reconstituted Complex9473491|9473491|9473491 CHD related
    CEBPA Reconstituted Complex9817600 No
    CEBPB Reconstituted Complex9817600|19652226|16651265|7651415 No
    CCND1 Reconstituted Complex9039267|9039267|16061635|9039267,11073968 CHD related
    SVIL Two-hybrid11792840 No
    NR0B2 Two-hybrid9773978|9773978|11861507,9773978 No
    IGF1R Affinity Capture-Western16113100 CHD related
    PAK6 Reconstituted Complex11773441|11773441 No
    POU4F1 Reconstituted Complex9448000|9448000 No
    POU4F2 Reconstituted Complex9448000|9448000 No
    REXO4 Reconstituted Complex10908561|10908561 No
    NR2C1 Affinity Capture-Western12093804|12093804|12093804 No
    AKAP13 Reconstituted Complex9627117|9627117|9627117 No
    TBP Reconstituted Complex11595744|11595744 No
    PPARGC1A Reconstituted Complex10748020|10748020 CHD related
    NCOA3 Reconstituted Complex11389589|16923966|14766010|20181721|19491275|19491275|17158759|11050174,15145444,11353774 No
    SHC1 Affinity Capture-Western11773443|11773443 No
    Tada3 Affinity Capture-Western12034840|12034840 No
    RNF4 Two-hybrid9710597 No
    PIAS2 Reconstituted Complex11117529 No
    TRIM24 Reconstituted Complex9115274|10598587|9115274,9632676,10598587 No
    NR2F6 Reconstituted Complex10713182 No
    ISL1 Affinity Capture-Western11043578|11043578|11043578 No
    NCOA7 Reconstituted Complex11971969|11971969 No
    NCOR1 Reconstituted Complex12145334|12145334 No
    JUN Reconstituted Complex11477071|17317669|11477071 CHD related
    ZNF398 Reconstituted Complex11779858|11779858 No
    SRA1 Protein-RNA11250900 No
    RLIM Affinity Capture-Western19117995|19117995 No
    PDLIM1 Affinity Capture-Western19117995 No
    LDB1 Reconstituted Complex19117995 No
    TRIM25 Affinity Capture-Western17418098|17418098|17418098 No
    KAT5 Affinity Capture-Western17418098|11591700 No
    HDAC7 Affinity Capture-Western19917725 No
    SP1 Co-localization19652226|16651265|16439465|15987735|15557281|15084343|17656465|17312152 No
    SIN3A Affinity Capture-Western19620290 No
    MTA2 Reconstituted Complex16645043 No
    AHRR Affinity Capture-Western18565642 No
    ING1 Reconstituted Complex14630091 No
    HDAC1 Affinity Capture-Western14506733|14506733|15557281|14722073|17312152 CHD related
    LMO4 Reconstituted Complex16288053|16288053 No
    SETD7 Protein-peptide18471979|18471979 No
    PGC Reconstituted Complex15784253 No
    ATAD2 Affinity Capture-Western17998543|17998543 No
    RPS6KA1 Biochemical Activity9528769|12093745,9528769,11507039,11139588,11432835 CHD related
    LRIF1 Reconstituted Complex17455211 No
    HDAC3 Co-localization14722073 CHD related
    PHB Reconstituted Complex17932104 No
    KAT6A Affinity Capture-Western17697320 No
    FOS Affinity Capture-Western17317669 CHD related
    HDAC2 Affinity Capture-Western17312152 CHD related
    SMAD3 Affinity Capture-Western20207742 CHD related
    SMURF1 Affinity Capture-Western20207742|20207742 No
    ACTN4 Affinity Capture-Western21078666|21078666 No
    AKT1 Biochemical Activity11139588|11139588 CHD related
    MED25 Two-hybrid17641689 No
    RPS6KA3 Affinity Capture-Western11432835|11507039,11139588,11432835,9528769 No
    AKT2 Biochemical Activity11507039|11507039,11139588,11432835,9528769 CHD related
    SF1 Two-hybrid11574675 No
    CUEDC2 Affinity Capture-Western21572428|17347654 No
    SKIL Affinity Capture-Western22227247|22227247 No
    SKI Affinity Capture-Western22227247 No
    KDM4B Affinity Capture-MS21502505|21502505|21502505 No
    SIRT1 Affinity Capture-Western21920899 CHD related
    CALM1 Reconstituted Complex11981030 No
    RXRA Far Western9121466 CHD related
    PPARG Far Western9121466 CHD related
    PGR Affinity Capture-Western22396492|22396492|12612073 No
    XPO1 Affinity Capture-Western22266855 No
    RAN Affinity Capture-Western22266855 No
    E2F1 Affinity Capture-Western22216287 CHD related
    RABGEF1 Affinity Capture-Western21356307 No
    TAB2 Affinity Capture-Western22249258 No
    PPP1CC Affinity Capture-Western17274640 No
    CDK11B Reconstituted Complex19122208|19122208 No
    SPOP Affinity Capture-Western18414007 No
    COPS5 Affinity Capture-Western15899841 No
    RBCK1 Affinity Capture-Western23042805|23042805 No
    RBM23 Reconstituted Complex15694343 No
    CHUK Co-localization15808510|15808510 CHD related
    CRIPAK Affinity Capture-Western16278681 No
    EIF3I yeast 2-hybrid10706629 No
    TAP1 in vitro9774463 CHD related
    BCAS2 in vitro;in vivo;yeast 2-hybrid15694360 No
    TCF20 in vitro;in vivo15831449 No
    GRB2 in vitro;in vivo15173068 CHD related
    CSNK2B in vitro7838153 No
    ARNT in vitro15837795 No
    WIPI1 in vitro15602573 No
    CHD9 in vitro16554032 No
    ITGB3BP in vitro;in vivo15254226 No
    NR1H4 in vivo17333335 No
    SMARCD3 in vitro14701856 No
    CUL4B in vivo17392787 No
    LCK in vitro;in vivo7539106 No
    PTPN6 in vitro7539106 No
    PTPN1 in vitro7539106 CHD related
    AR in vitro12389206 CHD related
    MAPK14 in vitro;in vivo12138194 CHD related
    RGS3 in vitro;in vivo12198596 No
    PAK1 in vitro;in vivo12374744 CHD related
    TNFRSF14 in vivo12093804 CHD related
    RFX4 in vivo10706293,1603086 No
    MKNK2 yeast 2-hybrid11013076 No
    RNF14 in vitro;in vivo10085091 No
    HSP90AB1 in vitro11795466 CHD related
    POLR1B in vitro11953755 No
    PRPF6 in vivo12039962 No
    RBM9 in vivo11875103 No
    TAF10 in vitro7923369 No
    LOH3CR2A in vitro;yeast 2-hybrid15474036 No
    MMS19 in vitro;yeast 2-hybrid11279242 No
    STRN in vitro;in vivo;yeast 2-hybrid15569929 No


    Involved FDA drugs

    StatusDrubBank IDNameIndicationATC Code
    approvedDB00255DiethylstilbestrolUsed in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.G03CB02;G03CC05;L02AA01
    approvedDB00269Chlorotrianisene"Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth."G03CA06
    approvedDB00286Conjugated Estrogens"For the treatment of moderate to severe vasomotor symptoms associated with the menopause, atrophic vaginitis, osteoporosis, hypoestrogenism due to hypogonadism, castration, primary ovarian failure, breast cancer (for palliation only), and Advanced androgen-dependent carcinoma of the prostate (for palliation only)"G03CA57
    approvedDB00294EtonogestrelFor use as a female contraceptive (depot).G03AC08
    approvedDB00304DesogestrelFor the prevention of pregnancy in women who elect to use this product as a method of contraception.G03AC09
    approvedDB00367LevonorgestrelFor the treatment of menopausal and postmenopausal disorders and alone or in combination with other hormones as an oral contraceptive.G03AC03;G03AD01
    approvedDB00396Progesterone"For progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency and for the treatment of secondary amenorrhea. Also used for the reduction of the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in postmenopausal women receiving estrogen replacement therapy, as well as treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer."G03AC06;G03DA02;G03DA03;G03DA04;L02AB02
    approvedDB00481Raloxifene"For the prevention and treatment of osteoporosis in post-menopausal women, as well as prevention and treatment of corticosteroid-induced bone loss. Also for the reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis or have a high risk for developing breast cancer."G03XC01
    approvedDB00539ToremifeneFor the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.L02BA02
    approvedDB00603Medroxyprogesterone"Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens."G03AC06;G03DA02;L02AB02
    approvedDB00655EstroneFor management of perimenopausal and postmenopausal symptoms.G03CA07;G03CC04
    approvedDB00675TamoxifenFor the treatment of breast cancer.L02BA01
    approvedDB00783Estradiol"For the treatment of urogenital symptoms associated with post-menopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria)."G03CA01;G03CA03;L02AA02;L02AA03
    approvedDB00823Ethynodiol DiacetateFor the prevention of pregnancy in women who elect to use this product as a method of contraception.
    approvedDB00882ClomifeneUsed mainly in female infertility due to anovulation (e.g. due to polycystic ovary syndrome) to induce ovulation. G03GB02
    approvedDB00890DienestrolFor use in the treatment of atrophic vaginitis and kraurosis vulvae.G03CB01;G03CC02
    approvedDB00947FulvestrantFor the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.L02BA03
    approvedDB00957NorgestimateFor the prevention of pregnancyG03AA11
    approvedDB00977Ethinyl Estradiol"For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive."G03CA01
    approved;nutraceuticalDB01065Melatonin"Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders. "N05CH01;N05CM17
    approved;withdrawnDB01108TrilostaneUsed in the treatment of Cushing's syndrome. It is normally used in short-term treatment until permanent therapy is possible.H02CA01
    approvedDB01183Naloxone"For the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol."V03AB15
    illicit;approvedDB01185Fluoxymesterone"In males, used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. In females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal."G03BA01
    approvedDB01196EstramustineFor the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostateL01XX11
    approvedDB01357MestranolMestranol was used as one of the first oral contraceptives.
    approvedDB01406DanazolFor the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.G03XA01
    approvedDB01431Allylestrenol"Allylestrenol was designed to be used for miscarriage prevention, prevention of premature labour and has been investigated for possible use in men for treatment for benign prostatic hyperplasia."G03DC01
    experimentalDB01645Genistein
    experimentalDB02615Compound 19
    experimentalDB02715Compound 18
    experimentalDB03742Compound 4-D
    experimentalDB03802"1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol"
    experimentalDB04471"2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol"
    approvedDB04573EstriolUsed as a test to determine the general health of an unborn fetus.G03CC06;G03CA04
    approvedDB04574Estropipate"Estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause, and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevent postmenopausal osteoporosis."
    approvedDB04575Quinestrol"Used in hormone replacement therapy, treating symptoms of menopause such as hot flashes. Also used to treat breast and prostate cancer."
    approvedDB06713NorelgestrominNorelgestromin is used for contraception and menopausal hormonal therapy. Norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy. G03AA13
    experimentalDB0687117-METHYL-17-ALPHA-DIHYDROEQUILENIN
    experimentalDB06898"4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol"
    experimentalDB06927[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
    experimentalDB07086"4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL"
    experimentalDB07087"4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL"
    experimentalDB07195"4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL"
    experimentalDB07567"(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL"
    experimentalDB07638"(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL"
    experimentalDB07678"(9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL"
    experimentalDB07707"(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL"
    experimentalDB077083-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
    experimentalDB077123-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
    experimentalDB07932"dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate"
    experimentalDB07933"(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL"
    experimentalDB07991N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
    experimentalDB08020"(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL"
    experimentalDB08047"4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol"
    experimentalDB08048"4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL"
    experimentalDB08320"DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE"
    experimentalDB08398"2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE"
    experimentalDB08595"4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL"
    experimentalDB08737"(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL"
    experimentalDB08773RALOXIFENE CORE